Neurons in the brains of mice tell them to stop eating when they’ve had enough food – and since people probably have the same ...

Discover how compounded semaglutide enhances the body's natural insulin function, aiding in blood sugar control and diabetes ...

Novo Nordisk today announced 2024 earnings, reporting a 26% increase in annual sales to ~$40.56bn. Read why I upgrade NVO ...

Use of a sodium-glucose cotransporter 2, or SGLT2, inhibitor combined with calorie restriction resulted in greater rates of type 2 diabetes remission compared with calorie restriction alone, according ...

Market uncertainty makes investors nervous about investing in speculative industries. But Wall Street has high hopes for ...

The use of blockbuster weight loss drugs has surged among young women, for whom the treatments can often be "liberating." ...

Danish pharmaceutical behemoth Novo Nordisk reported better-than-expected net profit in the fourth quarter, amid soaring ...

Viking Therapeutics is a clinical-stage biotech company focused on developing weight-loss therapies. Read why I rate VKTX ...

The discovery and development of GLP-1 receptor agonists for type 2 diabetes and obesity is a bench-to-bedside success story.1 Multiple GLP-1 receptor agonists are now in clinical use, such as ...